Investment analysts at StockNews.com started coverage on shares of VolitionRx (NYSE:VNRX - Get Free Report) in a report issued on Thursday. The brokerage set a "sell" rating on the stock.
Separately, Benchmark reiterated a "hold" rating on shares of VolitionRx in a research note on Friday, November 22nd.
Check Out Our Latest Stock Analysis on VolitionRx
VolitionRx Stock Performance
Shares of VNRX traded up $0.01 during trading on Thursday, reaching $0.70. The company's stock had a trading volume of 373,719 shares, compared to its average volume of 159,051. The company has a fifty day moving average of $0.69 and a two-hundred day moving average of $0.68. VolitionRx has a twelve month low of $0.43 and a twelve month high of $1.23.
Institutional Trading of VolitionRx
A hedge fund recently raised its stake in VolitionRx stock. Ground Swell Capital LLC lifted its holdings in shares of VolitionRx Limited (NYSE:VNRX - Free Report) by 78.8% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 45,959 shares of the company's stock after buying an additional 20,249 shares during the period. Ground Swell Capital LLC's holdings in VolitionRx were worth $28,000 at the end of the most recent reporting period. 8.09% of the stock is currently owned by institutional investors and hedge funds.
VolitionRx Company Profile
(
Get Free Report)
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.
See Also
Before you consider VolitionRx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and VolitionRx wasn't on the list.
While VolitionRx currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
